EASO Obesity Treatment Framework: Pharmacological Approach
“`html
Financial Conflicts of Interest Disclosure: Medical Professionals
Table of Contents
Overview
This document details disclosed financial conflicts of interest for a group of medical professionals as of October 3,2024. These disclosures are crucial for transparency in medical research and practice, ensuring objectivity and trust. The facts is compiled from a provided text and aims to present a clear and concise overview of each individual’s reported affiliations and financial relationships.
Individual Disclosures
J.L.B.
J.L.B. has received consulting fees and serves as an advisory board member for Novo Nordisk A/S. These fees are paid directly to her institution. This indicates a financial relationship with a pharmaceutical company specializing in diabetes and obesity care.
L.B.
L.B. has received honoraria from multiple pharmaceutical companies, including Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Pfizer, Bruno Farmaceutici, Regeneron, Rythm Pharmaceuticals, and Pronokal. These payments were received for speaking engagements and/or membership on advisory boards. This extensive list suggests broad engagement with companies in the metabolic and pharmaceutical sectors.
D.D.
D.D. has received speaker and advisory board fees from Boehringer-Ingelheim, Eli-Lilly, Novo Nordisk, and astrazeneca. Additionally, D.D. has received research grants from Eli Lilly,NovoNordisk,and Boehringer Ingelheim.This demonstrates both direct financial compensation for services and funding for research endeavors from these companies.
G.F.
G.F. has received honoraria from Eli Lilly, Novo Nordisk, Regeneron, and AstraZeneca for speaking engagements and advisory board participation.G.F. also receives honoraria as a member of the OPEN Spain Initiative. The OPEN Spain Initiative is a collaborative effort focused on obesity management, suggesting a commitment to advancing research and treatment in this area.
G.G.
G.G. has declared no conflicts of interest.
B.M.-T.
B.M.-T. has been awarded grants from the EASO New Clinical Investigator Award 2024 and the EFSD Rising Star 2024.Both awards are supported by the Novo Nordisk Foundation.This indicates recognition of B.M.-T.’s research potential and financial support from a foundation linked to a major pharmaceutical company.
Matteo Monami
Matteo Monami has received speaking fees from Astra Zeneca, bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, sanofi, and Novartis. He has also received research grants from Bristol myers Squibb. This extensive list highlights a notable involvement with numerous pharmaceutical companies, both through speaking engagements and research funding.
P.S.
P.S. has received honoraria and consulting fees from Boehringer Ingelheim, Chiesi, Novo Nordisk, Eli Lilly, Pfizer, and Roche as a member of advisory boards. This indicates a role in providing expert advice to these companies.
E.W.
E.W. has declared no conflicts of interest.
V.Y.
V.Y. has participated in advisory boards and delivered lectures sponsored by Novo Nordisk, Eli lilly, Rhythm, and Regeneron. This demonstrates engagement with these companies through both advisory roles and educational presentations.
Implications and Context
The disclosed financial relationships are common within the medical field, particularly in areas like diabetes, obesity, and metabolic disorders. Pharmaceutical companies often collaborate with medical professionals for research, advisory services, and educational initiatives. However, transparency regarding these relationships is vital to maintain public trust and ensure that medical decisions are based on scientific evidence rather than financial incentives.
It’s important to note that the existence of a financial relationship does not necessarily imply bias. However, these disclosures allow for critical evaluation of research findings and clinical recommendations. Patients and healthcare professionals should be aware of these potential conflicts of interest when considering treatment options.